Available from: Nguyen TMD
In addition, nearly 32 percent of people taking Zepbound lost at least a quarter of their body weight, compared to about 16 percent of those taking Wegovy, the study found
These effects help improve glycemic control in people with diabetes
Compan V, Pierredon S, Vanderperre B, Krznar P, Marchiq I, Zamboni N, et al
Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving beta-catenin